Market Research Report for 2025 delivers a comprehensive analysis of the industry's progress, examining both historical trends and the current market landscape. It provides key insights into ...

New data from the phase 3 MINT trial in adults living with autoimmune disorder generalised myasthenia gravis (gMG) – which ...

approval of the expanded indication of Alexion/AstraZeneca’s eculizumab (Soliris) for pediatric patients aged six years and older with generalized myasthenia gravis (gMG) who are anti ...

According to a release from the Muscular Dystrophy Association, Soliris (eculizumab, Alexion/AstraZeneca) is the first and only treatment available to address the neuromuscular disease in this ...

Five new agents to treat gMG have been approved, including three complement inhibitors -- eculizumab (Soliris), ravulizumab (Ultomiris), and zilucoplan (Zilbrysq) – and two neonatal FcRn ...

It has been 10 years since the first biosimilar was approved by the FDA. The grades on how the market for biosimilars has ...

Importantly, none of the AEs that were observed required the use of additional immunomodulatory agents such as eculizumab, sirolimus or rituximab.

Significant unmet need remains in PNH, a chronic, rare and potentially life-threatening blood disorder; a large proportion of patients can remain anemic and dependent on blood transfusions 3,4 ...

In the phase 1/2 INSPIRE DUCHENNE trial, interim data showed an average microdystrophin expression of 110% among participants ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Generalized ...